1例非功能性盆腔神经内分泌肿瘤的病例报告
A Case Report of Nonfunctional Pelvic Neuroendocrine Tumor
DOI: 10.12677/ACM.2023.13112591, PDF,   
作者: 张舒瑶:西安医学院研究生院,陕西 西安;李建辉*:陕西省人民医院肿瘤外科,陕西 西安
关键词: 神经内分泌瘤诊断治疗Neuroendocrine Tumor Diagnosis Treatment
摘要: 神经内分泌肿瘤是一种较为罕见的肿瘤类型,与肿瘤发生的位置无关,由肿瘤细胞起源的细胞种类有关,通常由能分泌多肽激素的神经内分泌细胞构成,肿瘤的临床症状通常与其的压迫部位及分泌的激素的不同而存在较大差异,压迫症状通常与压迫部位有关,包括腹胀腹痛、咳嗽气喘及尿频尿急等相关症状;激素分泌过度症状通常较为复杂,包括卓–艾综合征、肌无力综合征及库欣综合征等,在怀疑可能存在神经内分泌瘤时可通过CT、B超及相关激素血清含量进行诊断。非功能性神经内分泌瘤症状较轻,疾病指向性不明显,往往需要病理活检后才能诊断。外科手术治疗是神经内分泌瘤的主要治疗手段,手术的方式根据不同的肿瘤部位、大小及病理情况而定,本文报道1例我院收治的盆腔神经内分泌肿瘤临床治疗过程并进行文献回顾,为同道提供参考。
Abstract: Neuroendocrine tumor is a rare tumor type, which has nothing to do with the location of the tumor, but is related to the cell type from which the tumor cells originated. It is usually composed of neu-roendocrine cells that can secrete polypeptide hormones, and the clinical symptoms of the tumor are usually quite different from the compression sites and hormones secreted. The compression symptoms are usually related to the compression site, including abdominal distension, abdominal pain, cough, asthma, frequent urination and urgency. The symptoms of hypersecretion of hormones are usually complex, including Zollinger-Ellison syndrome, Lambert-Eaton Myasthenic Syndrome and Cushing syndrome, etc. When neuroendocrine tumors are suspected, CT scan, B-ultrasound and serum levels of related hormones can be diagnosed. The symptoms of non-functional neuroendo-crine tumors are mild, the disease orientation is not obvious, and need to be diagnosed after patho-logical biopsy. Surgical treatment is the main treatment for neuroendocrine tumors, and the surgi-cal method depends on different tumor locations, sizes and pathological conditions. This paper re-ports the clinical treatment process of a pelvic neuroendocrine tumor admitted to our hospital and reviews the literature, so as to provide reference for fellow practitioners.
文章引用:张舒瑶, 李建辉. 1例非功能性盆腔神经内分泌肿瘤的病例报告[J]. 临床医学进展, 2023, 13(11): 18448-18452. https://doi.org/10.12677/ACM.2023.13112591

参考文献

[1] Klöppel, G. (2017) Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications. Visceral Medicine, 33, 324-330. [Google Scholar] [CrossRef] [PubMed]
[2] Pan, W.-X., Zhang, X.-M., Hao, S.-L., et al. (2023) Progress in Immuno-therapy for Neuroendocrine Neoplasm of the Digestive System. World Journal of Gastroenterology, 29, 4174-4185. [Google Scholar] [CrossRef] [PubMed]
[3] Singh, S., Asa, S.L., Dey, C., et al. (2016) Diagnosis and Manage-ment of Gastrointestinal Neuroendocrine Tumors: An Evidence-Based Canadian Consensus. Cancer Treatment Reviews, 47, 32-45. [Google Scholar] [CrossRef] [PubMed]
[4] Ambrosini, V., Kunikowska, J., Baudin, E., et al. (2021) Consen-sus on Molecular Imaging and Theranostics in Neuroendocrine Neoplasms. European Journal of Cancer, 146, 56-73. [Google Scholar] [CrossRef] [PubMed]
[5] 高雨菡, 王萱, 薛华丹. 影像学在神经内分泌肿瘤合并肝转移患者早期治疗评价中的作用: 从解剖学到功能学[J]. 中国医学科学院学报, 2021, 43(6): 956-961.
[6] Mete, O. and Wenig, B.M. (2022) Update from the 5th Edition of the World Health Organization Classification of Head and Neck Tumors: Overview of the 2022 WHO Classification of Head and Neck Neuroendocrine Neoplasms. Head and Neck Pa-thology, 16, 123-142. [Google Scholar] [CrossRef] [PubMed]
[7] Duan, K. and Mete, O. (2016) Algorithmic Approach to Neuroendocrine Tumors in Targeted Biopsies: Practical Applications of Immunohistochemical Markers. Cancer Cytopathology, 124, 871-884. [Google Scholar] [CrossRef] [PubMed]
[8] Yao, J.C., Hassan, M., Phan, A., et al. (2008) One Hundred Years after “Carcinoid”: Epidemiology of and Prognostic Factors for Neuroendocrine Tumors in 35,825 Cases in the United States. Journal of Clinical Oncology, 26, 3063-3072. [Google Scholar] [CrossRef
[9] La Rosa, S. and Uccella, S. (2020) Classification of Neuroendo-crine Neoplasms: Lights and Shadows. Reviews in Endocrine and Metabolic Disorders, 22, 527-538. [Google Scholar] [CrossRef] [PubMed]
[10] Cui, J., Zhang, Y., Ren, X., et al. (2021) TBX1 Functions as a Tumor Activator in Prostate Cancer by Promoting Ribosome RNA Gene Transcription. Frontiers in Oncology, 10. [Google Scholar] [CrossRef] [PubMed]
[11] 徐建明, 梁后杰, 秦叔逵, 等. 中国胃肠胰神经内分泌肿瘤专家共识(2016年版) [J]. 临床肿瘤学杂志, 2016, 21(10): 927-946.
[12] Janson, E.T., Holmberg. L., Stridsberg. M., et al. (1997) Carcinoid Tumors: Analysis of Prognostic Factors and Survival in 301 Patients from a Referral Center. Annals of Oncology, 8, 685-690. [Google Scholar] [CrossRef
[13] Jensen, K.H., Hilsted, L., Jensen, C., et al. (2012) Chromogranin A is a Sensitive Marker of Progression or Regression in Ileo-Cecal Neuroendocrine Tumors. Scandinavian Journal of Gastroenterology, 48, 70-77. [Google Scholar] [CrossRef] [PubMed]
[14] Welin, S., Stridsberg, M., Cunningham, J., et al. (2009) Ele-vated Plasma Chromogranin A Is the First Indication of Recurrence in Radically Operated Midgut Carcinoid Tumors. Neuroendocrinology, 89, 302-307. [Google Scholar] [CrossRef] [PubMed]
[15] Arnold, R., Wilke, A., Rinke, A., et al. (2008) Plasma Chromogranin A as Marker for Survival in Patients with Metastatic Endocrine Gastroenteropancreatic Tumors. Clinical Gastroenterology and Hepatology, 6, 820-827. [Google Scholar] [CrossRef] [PubMed]
[16] Singh, S., Granberg, D., Wolin, E., et al. (2016) Patient-Reported Burden of a Neuroendocrine Tumor (NET) Diagnosis: Results From. JCO Global Oncology, 3, 43-53. [Google Scholar] [CrossRef